Renal Mass clinical trials at UCLA
1 research study open to eligible people
Showing trials for
SPECT/CT for the Characterization of Renal Masses
open to eligible people ages 18 years and up
This trial studies how well technetium Tc-99m sestamibi single-photon emission computed tomography/computed tomography (SPECT/CT) works on clinical decision making in patients with kidney tumors. Diagnostic procedures, such as technetium Tc-99m sestamibi SPECT/CT may be a less invasive way to check for kidney tumors.
Los Angeles, California
Our lead scientists for Renal Mass research studies include Brian Shuch.
Last updated: